Acta Neurochirurgica

, Volume 161, Issue 4, pp 761–765 | Cite as

Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients

  • Thibault Passeri
  • Pierre-Olivier ChampagneEmail author
  • Anne-Laure Bernat
  • Shunya Hanakita
  • Henri Salle
  • Emmanuel Mandonnet
  • Sébastien Froelich
Original Article - Tumor - Meningioma
Part of the following topical collections:
  1. Tumor – Meningioma



The relationship between increased meningioma incidence and growth and long-term hormonal therapy with cyproterone acetate (CPA) in women has been recently established in literature. Following the raise in awareness from hormonal treatment, we describe a potential relationship between the progesterone agonist nomegestrol acetate (NOMAC) and meningioma growth.


After implementation of a screening protocol to detect potential interactions between hormonal exposure and occurrence of meningioma, we identified patients taking NOMAC and newly diagnosed with a meningioma. NOMAC was stopped and those patients were followed tightly both clinically and radiologically. Retrospective volumetric analysis of the tumors was performed on the imaging.


Three patients were identified for the study. After cessation of the NOMAC, tumor shrinkage was documented for all meningiomas within the first month. Up to 70% of tumor volume reduction was observed during the first year of follow-up in one of them. None of the patients developed new symptoms.


We report the first cases of meningiomas responsiveness to discontinuation of hormonal therapy with NOMAC. Similarly to cases associated with long-term CPA intake, tumor reduction, and improvement of clinical symptoms can be observed after cessation of NOMAC.


Progestational agonist Meningioma Cyproterone acetate Nomegestrol acetate 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (name of institute/committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Patient consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Anda T, Honda M, Ishihara T, Kamei T (2014) Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report. Neurol Med Chir 54:327–330CrossRefGoogle Scholar
  2. 2.
    Bernat AL, Bonnin S, Labidi M, Aldahak N, Bresson D, Bouazza S, Froelich S (2018) Regression of giant olfactory groove meningioma and complete visual acuity recovery after discontinuation of cyproterone acetate. J Ophthalmic Vis Res 13:355–358CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bernat AL, Oyama K, Hamdi S, Mandonnet E, Vexiau D, Pocard M, George B, Froelich S (2015) Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir 157:1741–1746CrossRefPubMedGoogle Scholar
  4. 4.
    Botella C, Coll G, Lemaire JJ, Irthum B (2015) Intra cranial meningiomas and long term use of cyproterone acetate with a conventional dose in women. A report of two cases of tumor decrease after treatment withdrawal. Neuro-Chirurgie 61:339–342CrossRefPubMedGoogle Scholar
  5. 5.
    Cebula H, Pham TQ, Boyer P, Froelich S (2010) Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient. Acta Neurochir 152:1955–1956CrossRefPubMedGoogle Scholar
  6. 6.
    Custer BS, Koepsell TD, Mueller BA (2002) The association between breast carcinoma and meningioma in women. Cancer 94:1626–1635CrossRefPubMedGoogle Scholar
  7. 7.
    Durmaz R, Deliorman S, Isiksoy S, Uyar R, Tel E (1999) Luteinizing hormone releasing hormone increases proliferation of meningioma cells in vitro. Arch Physiol Biochem 107:286–291PubMedGoogle Scholar
  8. 8.
    Gil M, Oliva B, Timoner J, Macia MA, Bryant V, de Abajo FJ (2011) Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol 72:965–968CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Goncalves AM, Page P, Domigo V, Meder JF, Oppenheim C (2010) Abrupt regression of a meningioma after discontinuation of cyproterone treatment. AJNR Am J Neuroradiol 31:1504–1505CrossRefPubMedGoogle Scholar
  10. 10.
    Hirota K, Fujita T, Akagawa H, Onda H, Kasuya H (2014) Spontaneous regression together with increased calcification of incidental meningioma. Surg Neurol Int 5:73CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Huang Q, Chen X, Zhu Y, Cao L, Riviere JE (2015) Pharmacokinetics, tissue distribution, and excretion of nomegestrol acetate in female rats. Eur J Drug Metab Pharmacokinet 40:435–442CrossRefPubMedGoogle Scholar
  12. 12.
    Kalamarides M, Peyre M (2017) Dramatic shrinkage with reduced vascularization of large meningiomas after cessation of progestin treatment. World Neurosurg 101:814.e7–814.e10CrossRefGoogle Scholar
  13. 13.
    Kerschbaumer J, Freyschlag CF, Stockhammer G, Taucher S, Maier H, Thome C, Seiz-Rosenhagen M (2016) Hormone-dependent shrinkage of a sphenoid wing meningioma after pregnancy: case report. J Neurosurg 124:137–140CrossRefPubMedGoogle Scholar
  14. 14.
    Khanna RK, Arsene S, Velut S, Zemmoura I, Gaillot K, Pisella PJ, Le Lez ML (2017) Spheno-orbital meningioma during pregnancy: case report of a 37-year-old woman. J Fr Ophtalmol 40:e361–e366CrossRefPubMedGoogle Scholar
  15. 15.
    Lee KL, Terris MK (2003) Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma. Urology 62:351PubMedGoogle Scholar
  16. 16.
    Lello S (2010) Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs 70:541–559CrossRefPubMedGoogle Scholar
  17. 17.
    Li Q, Coulson H, Klaassen Z, Sharma S, Ramalingam P, Moses KA, Terris MK (2013) Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma. Prostate Cancer Prostatic Dis 16:387CrossRefPubMedGoogle Scholar
  18. 18.
    Lusis EA, Scheithauer BW, Yachnis AT, Fischer BR, Chicoine MR, Paulus W, Perry A (2012) Meningiomas in pregnancy: a clinicopathologic study of 17 cases. Neurosurgery 71:951–961CrossRefPubMedGoogle Scholar
  19. 19.
    Marques P, Skorupskaite K, George JT, Anderson RA (2000) Physiology of GNRH and gonadotropin secretion Accessed 20 Dec 2018
  20. 20.
    Mueck AO, Sitruk-Ware R (2011) Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 76:531–539CrossRefPubMedGoogle Scholar
  21. 21.
    Olson JJ, Beck DW, Schlechte J, Loh PM (1986) Hormonal manipulation of meningiomas in vitro. J Neurosurg 65:99–107CrossRefPubMedGoogle Scholar
  22. 22.
    Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-oncology 19:v1–v88CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Perrot-Applanat M, Groyer-Picard MT, Kujas M (1992) Immunocytochemical study of progesterone receptor in human meningioma. Acta Neurochir 115:20–30CrossRefPubMedGoogle Scholar
  24. 24.
    Perry A, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF, Weaver A, Gutmann DH (2000) Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 59:872–879CrossRefPubMedGoogle Scholar
  25. 25.
    Pravdenkova S, Al-Mefty O, Sawyer J, Husain M (2006) Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg 105:163–173CrossRefPubMedGoogle Scholar
  26. 26.
    Tsutsui T, Miyashita K, Sabit H, Fukui I, Hayashi Y, Mizokami A, Ikeda H, Nagatani H, Nakada M (2016) Acute progression of recurrent meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer. World Neurosurg 91:670.e671–670.e676CrossRefGoogle Scholar
  27. 27.
    Yang LP, Plosker GL (2012) Nomegestrol acetate/estradiol: in oral contraception. Drugs 72:1917–1928CrossRefPubMedGoogle Scholar
  28. 28.
    Yilmaz A, Kizilay Z, Sair A, Avcil M, Ozkul A (2016) Spontaneous regression of an incidental spinal meningioma. Open Access Maced J Med Sci 4:128–130CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurosurgery, Lariboisiere HospitalUniversity of Paris DiderotParisFrance

Personalised recommendations